Company intelligence / Profile preview

Alphabiome

Not specified (likely United States based on context)abiomcorp.com ↗

Ownership: Private
Development stage: Commercial

Overview

Alphabiome has developed an advanced AI-powered platform that deciphers microbial DNA to predict individual drug responses. The company claims its technology sets a new standard in personalized medicine by enabling more precise treatment selection based on the patient’s unique microbiome profile. No clinical trial results are published as it appears to be a data/platform company rather than a therapeutic developer.

Therapeutic areas: Other
Modalities: Microbial therapyAI-driven diagnostics
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Alphabiome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alphabiome.

Explore the full profile